09:33pm Friday 20 October 2017

Discovery of Key Regulatory Factor May Offer New Treatment Target for Allergic Diseases

By identifying a regulatory protein that is key to the mechanism and then blocking its production in laboratory tests, the researchers were able to define a protein responsible for causing the inflammation, said Mark H. Kaplan, Ph.D., professor of pediatrics and of microbiology and immunology at the IU School of Medicine, located on the campus of Indiana University –Purdue University, Indianapolis. The research is being reported online today in the June 2010 issue of the journal Nature Immunology.

The IU research team was investigating the chain of events – and proteins – that result in the production of a substance called IL-9, which causes a variety of inflammatory responses, such as mucus production in the lungs. Recently other scientists had discovered the existence of a new type of T-cell, one of the body’s immune system cells used to ward off infections. That newly discovered type of T-cell was found to produce IL-9. Kaplan’s team, in turn, found that a regulatory factor called PU.1 is necessary for the development of the new type of T-cell.

“We see increased IL-9 production in patients with allergic disease – allergies, asthma, eczema,” said Dr. Kaplan, director of pediatric pulmonary basic research and investigator at the Herman B Wells Center for Pediatric Research.

“Effectively targeting PU.1 to prevent its activation could lead to improved treatments for patients who must deal with the inflammation caused by these allergic diseases,” Dr. Kaplan said.

The research received support from the National Institutes of Health and the Riley Children’s Foundation. Dr. Kaplan has recently received a $1.9M grant from the National Institutes of Health to continue research on this factor.

# # #

Media Contact:

Eric Schoch
(317) 274-7722
eschoch@iupui.edu


Share on:
or:

MORE FROM Medical Breakthroughs

Health news